Metabolomics to Reveal Diagnostic Biomarkers in CA19-9 Negative Pancreatic Ductal Adenocarcinoma: A Cross-Sectional Study
Journal of Proteome Research · 2026
DOI: 10.1021/acs.jproteome.5c00615 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Journal of Proteome Research, 2026. Verfasst von Shu-Jun Gu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Jiaxing 314000 Zhejiang, China. Hauptthemen laut MEDLINE: CA-19-9 Antigen, Carcinoma, Pancreatic Ductal, Metabolomics, Biomarkers, Tumor. Die Arbeit nennt 50 Literaturangaben. Gefördert von: Medical Science and Technology Project of Zhejiang Province, National Oncology Clinical Key Speciality.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) with negative carbohydrate antigen 19-9 (CA19-9) lacks effective diagnostic and monitoring indicators. We aimed to identify metabolic characteristics in such patients through metabolomics and explored potential plasma biomarkers. In this study, untargeted metabolomics analysis was performed on plasma samples from 30 healthy controls and 30 CA19-9 positive and 30 CA19-9 negative PDAC patients by using liquid chromatograph-mass spectrometer (LC-MS) technology. Compared with healthy controls, 36 differential metabolites were upregulated, and 3 differential metabolites were downregulated in the plasma of CA19-9 negative PDAC patients. Four upregulated differential metabolites, including palmitic amide, dolichol phosphate, cholesteryl acetate, and vitamin A2 aldehyde, were potential biomarkers for diagnosing CA19-9 negative PDAC patients. Enrichment analysis of KEGG pathways showed that glycine and threonine metabolism, tyrosine and tryptophan biosynthesis, thiamine metabolism, etc., were disrupted in CA19-9 negative PDAC patients. In summary, we determined the metabolic heterogeneity in PDAC patients with normal CA19-9 levels. The detected metabolic biomarkers may offer new approaches for the clinical early diagnosis of CA19-9 negative PDAC in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Jiaxing 314000 Zhejiang, China.
- Department of Hepatobiliary and Pancreatic Surgery, First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Jiaxing 314000 Zhejiang, China.
ORCID-Profile: Shu-Jun Gu
Förderung
- Medical Science and Technology Project of Zhejiang Province
- National Oncology Clinical Key Speciality
Zitieren
APA
Gu, S. J., Xu, L., Zhou, H. K., & Yang, J. (2026). Metabolomics to Reveal Diagnostic Biomarkers in CA19-9 Negative Pancreatic Ductal Adenocarcinoma: A Cross-Sectional Study. Journal of Proteome Research. https://doi.org/10.1021/acs.jproteome.5c00615
Vancouver
Gu SJ, Xu L, Zhou HK, Yang J. Metabolomics to Reveal Diagnostic Biomarkers in CA19-9 Negative Pancreatic Ductal Adenocarcinoma: A Cross-Sectional Study. Journal of Proteome Research. 2026. doi:10.1021/acs.jproteome.5c00615
BibTeX
@article{Gu2026,
author = {Gu, Shu-Jun and Xu, Liu and Zhou, Hong-Kun and Yang, Jie},
title = {Metabolomics to Reveal Diagnostic Biomarkers in CA19-9 Negative Pancreatic Ductal Adenocarcinoma: A Cross-Sectional Study},
journal = {Journal of Proteome Research},
year = {2026},
doi = {10.1021/acs.jproteome.5c00615}
}
EUVIMED